179 related articles for article (PubMed ID: 22584777)
1. Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia.
Goldberg JM; Scully RE; Sallan SE; Lipshultz SE
J Pediatr Hematol Oncol; 2012 Jul; 34(5):395-7. PubMed ID: 22584777
[TBL] [Abstract][Full Text] [Related]
2. Sudden death of a patient in complete remission after anthracycline therapy for acute lymphoblastic leukemia.
Tsuda N; Oka R; Kajino H; Kajino M; Okuno A
Pediatr Int; 2000 Jun; 42(3):319-21. PubMed ID: 10881596
[No Abstract] [Full Text] [Related]
3. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
Lipshultz SE; Anderson LM; Miller TL; Gerschenson M; Stevenson KE; Neuberg DS; Franco VI; LiButti DE; Silverman LB; Vrooman LM; Sallan SE;
Cancer; 2016 Mar; 122(6):946-53. PubMed ID: 26762648
[TBL] [Abstract][Full Text] [Related]
4. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
Lipshultz SE; Colan SD; Gelber RD; Perez-Atayde AR; Sallan SE; Sanders SP
N Engl J Med; 1991 Mar; 324(12):808-15. PubMed ID: 1997853
[TBL] [Abstract][Full Text] [Related]
5. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
[TBL] [Abstract][Full Text] [Related]
7. Late cardiotoxicity of anthracyclines in children with acute leukemia.
Zalewska-Szewczyk B; Lipiec J; Bodalski J
Klin Padiatr; 1999; 211(4):356-9. PubMed ID: 10472576
[TBL] [Abstract][Full Text] [Related]
8. Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia.
Ruggiero A; De Rosa G; Rizzo D; Leo A; Maurizi P; De Nisco A; Vendittelli F; Zuppi C; Mordente A; Riccardi R
Int J Clin Oncol; 2013 Oct; 18(5):927-33. PubMed ID: 22911020
[TBL] [Abstract][Full Text] [Related]
9. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic markers of anthracycline-induced cardiomyopathy in children with acute leukemia].
Shatyns'ka TV
Lik Sprava; 2014; (3-4):20-6. PubMed ID: 25286593
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
12. The value of echocardiography versus cardiac troponin I levels in the early detection of anthracycline cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up.
Oztarhan K; Guler S; Aktas B; Arslan M; Salcioglu Z; Aydogan G
Pediatr Hematol Oncol; 2011 Aug; 28(5):380-94. PubMed ID: 21699467
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study.
Samosir SM; Utamayasa IKA; Andarsini MR; Rahman MA; Ontoseno T; Hidayat T; Ugrasena IDG; Larasati MCS; Cahyadi A
Asian Pac J Cancer Prev; 2021 May; 22(5):1407-1412. PubMed ID: 34048168
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
[TBL] [Abstract][Full Text] [Related]
15. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Silber JH
Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791
[No Abstract] [Full Text] [Related]
16. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
Nysom K; Holm K; Lipsitz SR; Mone SM; Colan SD; Orav EJ; Sallan SE; Olsen JH; Hertz H; Jacobsen JR; Lipshultz SE
J Clin Oncol; 1998 Feb; 16(2):545-50. PubMed ID: 9469339
[TBL] [Abstract][Full Text] [Related]
17. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
18. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
Lipshultz SE; Miller TL; Scully RE; Lipsitz SR; Rifai N; Silverman LB; Colan SD; Neuberg DS; Dahlberg SE; Henkel JM; Asselin BL; Athale UH; Clavell LA; Laverdière C; Michon B; Schorin MA; Sallan SE
J Clin Oncol; 2012 Apr; 30(10):1042-9. PubMed ID: 22370326
[TBL] [Abstract][Full Text] [Related]
19. Cardiac autonomic dysfunction in survivors of acute lymphoblastic leukemia in childhood.
Kamath MV; Halton J; Harvey A; Turner-Gomes S; McArthur A; Barr RD
Int J Oncol; 1998 Mar; 12(3):635-40. PubMed ID: 9472104
[TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.
Chow EJ; Aggarwal S; Doody DR; Aplenc R; Armenian SH; Baker KS; Bhatia S; Blythe N; Colan SD; Constine LS; Freyer DR; Kopp LM; Laverdière C; Leisenring WM; Sasaki N; Vrooman LM; Asselin BL; Schwartz CL; Lipshultz SE
J Clin Oncol; 2023 Apr; 41(12):2248-2257. PubMed ID: 36669148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
